Diffuse large B-cell lymphoma (DLBCL)

DLBCL is the most common aggressive non-Hodgkin's lymphoma (NHL), comprising approximately 30% of all NHLs^1-3 (Table 1 for classification of B-cell lymphomas).

• The median age at diagnosis is 64 years⁴
• Although significant strides have been made in the treatment of DLBCL, only approximately half of patients remain disease free⁵
• Some patients either relapse after treatment or have primary refractory disease.^3,5 Extensive research is ongoing to help improve long-term progression-free survival and overall survival in these patients^6-8
• Although differential treatment based on prognostic markers is not yet a viable option, this approach is under continued exploration and may impact how treatments are used in the future⁷

Table 1. World Health Organization (WHO) classification of B-cell lymphomas.²

View References for this site section